Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bionomics Ltd Signs Option And License Agreement With Merck & Co Inc


Tuesday, 30 Jul 2013 11:34pm EDT 

Bionomics Ltd announced an agreement with Merck, known as MSD outside the United States and Canada, to discover and develop small molecule candidates for the treatment of chronic pain, including neuropathic pain. Under the terms of the agreement, Merck will have the option to exclusively license a compound from Bionomics for development and commercialisation. In return, Bionomics may receive option exercise fees and development and regulatory payments of up to USD172 million. Bionomics may also be eligible for undisclosed royalties on net sales of products from the collaboration. Bionomics retains the right to develop and commercialise certain compounds for which Merck does not exercise option. The initial period of the research program will be two years. 

Company Quote

57.46
0.25 +0.44%
24 Dec 2014